Droperidol on Prevention of Cannabis Hyperemesis Syndrome

Droperidol on Prevention of Emesis From Cannabinoid Hyperemesis Syndrome

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05244460

Acronym

DOPE

Enrollment

Registered

2022-02-17

Start date

2021-12-02

Completion date

2023-01-31

Last updated

2023-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cannabis Hyperemesis Syndrome

Brief summary

The purpose of this study is to assess the efficacy of droperidol as a treatment of cannabinoid hyperemesis syndrome.

Detailed description

Patients presenting to the Emergency Department with nausea, vomiting and/or abdominal pain with a significant history of cannabis use and symptoms in a cyclic pattern will be assessed for study inclusion. After given written informed consent, patients will be treated with droperidol and diphenhydramine and symptoms will be assessed using a visual analog scale at time intervals up to 120 minutes. Patient will then be contacted at 24 and 48 hour intervals to assess symptoms on the same scale. This is a multicenter, prospective interventional study with results compared to a historical cohort using haloperidol.

Interventions

DRUGDroperidol Injectable Product

Treatment

DRUGDiphenhydramine

Treatment

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* aged 18 years of age or older and presenting with cannabis hyperemesis syndrome requiring intravenous medication.

Exclusion criteria

* any patient with a contraindication to the use of droperidol * Corrected QT interval on ECG greater than 440 milliseconds for males and greater than 450 milliseconds for females * any prisoners * pregnant females.

Design outcomes

Primary

Measure	Time frame	Description
Change from baseline in symptoms after treatment with droperidol and diphenhydramine	Baseline, 30 minutes, 60 minutes and 120 minutes. Then at 24 hours and 48 hours.	The Visual Analog Scale is a 100-mm patient-reported score measurement used to assess nausea and/or vomiting and/or abdominal pain. Possible scores range from 0 (symptom-free) to 10 (worst possible symptom)

Countries

United States

Contacts

Primary ContactTodd Bolotin, MD

tbolotin@mercy.com3302193838

Backup ContactQuincy Chopra, MD

qchopra@mercy.com4128059742

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026